StreetInsider.com News Articles

Voyager Therapeutics (VYGR) Tops Q4 EPS by 5c

Mon, 09 Mar 2026 16:18:49 -0400

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.46), $0.05 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.34 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

Form 8-K Voyager Therapeutics, For: Mar 09

Mon, 09 Mar 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260309/26131945.html

Form 8-K Voyager Therapeutics, For: Mar 09

Mon, 09 Mar 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260309/26131945.html

Form 10-K Voyager Therapeutics, For: Dec 31

Mon, 09 Mar 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260309/26131904.html

Form 10-K Voyager Therapeutics, For: Dec 31

Mon, 09 Mar 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260309/26131904.html

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Mon, 09 Mar 2026 16:01:00 -0400

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

- Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 -

- Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile -

- Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 -

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Swartz Robin

Thu, 26 Feb 2026 09:48:00 -0400

si-local-file:///var/storage/secattach/20260226/26066127.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Swartz Robin

Thu, 26 Feb 2026 09:48:00 -0400

si-local-file:///var/storage/secattach/20260226/26066127.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Jorgensen Nathan D.

Thu, 26 Feb 2026 09:47:00 -0400

si-local-file:///var/storage/secattach/20260226/26066117.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Jorgensen Nathan D.

Thu, 26 Feb 2026 09:47:00 -0400

si-local-file:///var/storage/secattach/20260226/26066117.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Sandrock Alfred

Thu, 26 Feb 2026 09:47:00 -0400

si-local-file:///var/storage/secattach/20260226/26066121.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Sandrock Alfred

Thu, 26 Feb 2026 09:47:00 -0400

si-local-file:///var/storage/secattach/20260226/26066121.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Carter Todd Alfred

Thu, 26 Feb 2026 09:44:00 -0400

si-local-file:///var/storage/secattach/20260226/26066097.html

Form 4 Voyager Therapeutics, For: Feb 24 Filed by: Carter Todd Alfred

Thu, 26 Feb 2026 09:44:00 -0400

si-local-file:///var/storage/secattach/20260226/26066097.html